Table 2.
Effectiveness outcomes
| Outcome | Rivaroxaban N = 32,078 # of events (%/year) |
Warfarin N = 83,971 # of events (%/year) |
PS overlap weighted HR (95%CI) |
|---|---|---|---|
| Stroke, systemic embolism, vascular death | 3497 (3.79) | 10,077 (4.19) | 0.91 (0.88–0.95) |
| Stroke, systemic embolism, myocardial infarction, vascular death | 4074 (4.42) | 11,420 (4.76) | 0.94 (0.90–0.97) |
| Stroke or systemic embolism | 1219 (1.31) | 3275 (1.34) | 0.97 (0.90–1.04) |
| Stroke, myocardial infarction, vascular death | 4010 (4.34) | 11,252 (4.69) | 0.94 (0.90–0.97) |
| Ischemic stroke | 1026 (1.10) | 2519 (1.05) | 1.05 (0.97–1.14) |
| Systemic embolism | 128 (0.13) | 420 (0.16) | 0.82 (0.66–1.02) |
| Myocardial infarction | 898 (0.99) | 2267 (0.95) | 1.04 (0.96–1.14) |
| Vascular death | 2598 (2.81) | 7641 (3.18) | 0.90 (0.86–0.95) |
CI confidence interval, HR hazard ratio, PS propensity score